Press Release

<<  Back
Printer Friendly Version   View printer-friendly version
BioTime Co-CEO Dr. Michael West Presents at Biomedical Innovation for Healthy Longevity, International Conference
April 26, 2016

Presentation topics include:

• BioTime’s Products in Development Addressing the Large and Growing Markets in Age-Related Degenerative Disease; and

• New Insights into the Fundamental Biology of Human Aging


ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 26, 2016-- BioTime, Inc. (NYSE MKT:BTX) announced that Co-Chief Executive Officer Michael D. West, Ph.D. delivered a presentation today at “Biomedical Innovation for Healthy Longevity, International Conference” in St. Petersburg, Russia.

Dr. West’s presentation is titled “Applied Gerontology: The Regenerative Medicine Revolution” and describes the application of BioTime'sPureStem® technology for the robust and reproducible generation of diverse cell types for applications in aging. The presentation is available on BioTime's website at

The four-day conference features scientific leaders from around the world to discuss recent breakthroughs in understanding the aging process, as well as companies and institutions focused on applying the technologies to human aging.

More information on the conference is available at

Background on Regenerative Medicine and Aging

Age-related degenerative diseases are commonly associated with the loss or dysfunction of the cells in various tissues of the body. The clocking mechanism for these changes may be the fact that human cells have a finite capacity to replicate themselves in response to injury, a phenomenon called the “Hayflick Limit.” Dr. West led the effort in the mid-1990s that led to the identification of the immortalizing gene called “telomerase” that could rewind the clock of cellular aging in human cells. Indeed, the administration of telomerase allows human cells to escape the Hayflick limit and replicate indefinitely, a phenomenon designated “cell immortalization.”

Since that time, BioTime has demonstrated the youthful status of its PureStem® cell types and even the reversal of the developmental aging of aged human cells by transcriptional reprogramming. It has emerged as a significant leader in pluripotent cell technology, with a product pipeline addressing age-related macular degeneration, orthopedic disorders of aging, age-related metabolic disorders, as well as other disease applications. A recent open access review by Dr. West describes the linkage of these insights into human aging and the strategies to intervene in the biology of human aging and is available for free download.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent cell assets. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In order to efficiently advance product candidates through the clinical trial process, we have historically created operating subsidiaries for each program and product line. This approach has fostered efficient use of resources and reduced shareholder dilution as compared to strategies commonly deployed by the biotechnology industry, as the various programs and product lines have advanced through basic research and animal studies. We and our subsidiaries now have four therapeutic product candidates in human clinical trials, each of which addresses a large market opportunity. In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime'sSecurities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:


Source: BioTime, Inc.

BioTime, Inc.
Dan L. Lawrence, 510-775-0510
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Media Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890